---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-058636"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2026-05-11T20:05:35+00:00"
generated_at: "2026-05-11T22:48:33.659314+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics Q1 net loss $0.13/sh; Phase 1b biomarker data support GT-02287

## Summary
- Q1 net loss $0.13 per share vs $0.16; R&D $2.8M, G&A $2.6M; cash $16.5M as of March 31, 2026.
- Phase 1b extension for GT-02287 shows GluSph in CSF decreased 81% in elevated baseline participants after 90 days.
- MDS-UPDRS scores stable over 150 days; 14 of 16 participants completed five months of dosing as of March 2026.
- Expecting FDA IND clearance for GT-02287 in Q2 2026 and Phase 2 start in Q3 2026.
- New allosteric modulator GT-04686 ready for IND-enabling studies; presented at AD/PD 2026.

## SEC filing metadata
- accession: 0001104659-26-058636
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2026-05-11T20:05:35+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465926058636/0001104659-26-058636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465926058636/ganx-20260511x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-058636
- JSON: https://secwatch.observer/filing/0001104659-26-058636.json
- Plain text: https://secwatch.observer/filing/0001104659-26-058636.txt

## Key facts
- Earnings Releases
  Gain Therapeutics, Inc. reported first quarter ended March 31, 2026 results: EPS $0.13 per share, basic and diluted.
  - Period: first quarter ended March 31, 2026
  - EPS: $0.13 per share, basic and diluted
  - Result: reported results
  source text: Net loss for the three months ended March 31, 2026, was $0.13 per share, basic and diluted, compared to $0.16 per share, basic and diluted, for the three months ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465926058636/0001104659-26-058636-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.